NCT02604693View on ClinicalTrials.gov

Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)

CompletedOBSERVATIONAL
Enrollment

148

Participants

Timeline

Start Date

December 14, 2014

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Chronic Beryllium Disease
Interventions
OTHER

Nothing

No interventions will be administered.

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
lead

National Jewish Health

OTHER

NCT02604693 - Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD) | Biotech Hunter | Biotech Hunter